Risk Factor for Erythropoietin Resistance in Hemodialysis Patient : Literature Review
DOI:
https://doi.org/10.12928/admj.v1i2.3131Keywords:
Risk Factor Erythropoietin, Resistance, Hemodialysis, Renal FailureAbstract
Anaemia become the complication of chronic kidney disease (CKD) which was caused by decreasing of erythropoietin. Erythropoietin stimulating agent (ESA) therapy is one of therapy to overcome the problem, but until 34% of patients have lack of response to ESA treatment. Anaemia in CKD related to the worsen of the diseases, quality of life, and mortality of patients. Decreasing of the response to erythropoietin need to be evaluated to correct anaemic condition. This review is aim to explain the risk factor for erythropoietin resistance. The literature for this review was collected through PUBMED and google scholar. Erythropoietin is glycoprotein secreted 90% by interstitial cells of kidney and 10% by liver cells. The functions of erythropoietin are stimulate the proliferation and cells differentiation in bone marrow, and enhance erythropoiesis. Renal damage can inhibit the secretion of erythropoietin. In patients with ESA treatment, risk factors for resistance are iron deficiency, inadequate haemodialysis, inflammation, hyperparathyroid, nutrition disturbance, antibody mediated Pure Red Cell Aplastic (PRCA). The risk factor can be influenced by genetic variation. Conclusion of this review, there are several factor that influence the response of erythropoietin in hemodialisa patients. Hence, study related anaemia in CKD need further study to optimalize the treatment.
References
Abella, V. et al. (2017) ‘Leptin in the interplay of inflammation, metabolism and immune system disorders’, Nature Reviews Rheumatology. Nature Publishing Group, 13(2), pp. 100– 109. doi: 10.1038/nrrheum.2016.209.
Akizawa, T. et al. (2018) ‘Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review’, Therapeutic Apheresis and Dialysis, 22(5), pp. 444–456. doi: 10.1111/1744-9987.12712.
Al-hilali, N., Al-humoud, H. and Ninan, T. (2007) ‘Does Parathyroid Hormone Affect Erythropoietin Therapy in Dialysis Patients ?’, 13110, pp. 63–67. doi: 1 0.1159/000096143.
Alves, M. T. et al. (2015) ‘Resistance of dialyzed patients to erythropoietin’, Revista Brasileira de Hematologia e Hemoterapia, 37(3), pp. 190–197. doi: 10.1016/j.bjhh.2015.02.001.
Amnuay, K. et al. (2019) ‘Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients’, Hematology Reports, 11, p. 8183. doi: 10.4081/hr.2019.8183.
Arfian, N. et al. (2018) ‘Prolonged Kidney Ischemia-Reperfusion Injury Associates with Inflammation , Vascular Remodelling , and Myofibroblast Formation’, J Med Sci, 50(1), pp. 1–14.
Arvedson, T. L. and Sasu, B. J. (2009) ‘Role and regulation of iron metabolism in erythropoiesis and disease’, Erythropoietins, Erythropoietic Factor and Erythropoiesis, 1, pp. 279–298.
Attallah, N. et al. (2006) ‘Effect of Intravenous Ascorbic Acid in Hemodialysis Patients With EPO-Hyporesponsive Anemia and Hyperferremia’, American Journal of Kidney Diseases, 47(4), pp. 644–654. doi: 10.1053/j.ajkd.2005.12.025.
Babitt, J. L. and Lin, H. Y. (2012) ‘Mechanisms of anemia in CKD’, Journal of the American Society of Nephrology, 23(10), pp. 1631–1634. doi: 10.1681/ASN.2011111078.
Bennett, L. F. et al. (2019) ‘Inflammation induces stress erythropoiesis through heme-dependent activation of SPI-C’, 7336(September).
Besarab, A. et al. (2015) ‘Roxadustat ( FG-4592 ): Correction of Anemia in Incident Dialysis Patients’, pp. 1–9. doi: 10.1681/ASN.2015030241.
Borelli, P. et al. (2007) ‘Reduction of erythroid progenitors in protein – energy malnutrition’, pp. 307–314. doi: 10.1017/S0007114507172731.
Casadevall, N. (2005) ‘What is antibody-mediated pure red cell aplasia ( PRCA )?’, Nephrol Dial Transplant, pp. 3–8. doi: 10.1093/ndt/gfh1088.
Chandran, M. and Wong, J. (2019) ‘Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease : An Endocrine and Renal Perspective’, Indian Journal of Endocrinology and Metabolism, 23(4), pp. 391–399. doi: 10.4103/ijem.IJEM.
Chen, M. P. et al. (2016) ‘Circulating growth arrest ‑ specific protein 6 levels are associated with erythropoietin resistance in hemodialysis patients’, SpringerPlus. Springer International Publishing. doi: 10.1186/s40064-016-1681-z.
Christie, M. et al. (2015) ‘The Role of Protein Excipient in Driving Antibody Responses to Erythropoietin’, Journal of Pharmaceutical Sciences. Elsevier Masson SAS, 104(12), pp. 4041–4055. doi: 10.1002/jps.24639.
Conner, T. A. et al. (2012) ‘Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose’, pp. 961– 969. doi: 10.1007/s10534-012-9562-6.
Corredor, Z. et al. (2020) ‘Genetic Variants Associated with Chronic Kidney Disease in a Spanish Population’, pp. 1–11. doi: 10.1038/s41598-019-56695-2.
Farida, L. S., Thaha, M. and Susanti, D. (2018) ‘Characteristics of Patients with End-Stage Renal Disease at Dialysis Unit Dr . Soetomo General Hospital Surabaya’, 01(02), pp. 97–100.
Finberg, K. E. (2013) ‘Regulation of systemic iron homeostasis’, current opinion hematology, 20(3), pp. 208–214. doi: 10.1097/MOH.0b013e32835f5a47.
Fock, R. A. (2004) ‘Haematological alterations in protein malnutrition’, 26(1), pp. 49–56.
Fouque, D. (2003) ‘Nutritional Requirements in Maintenance Hemodialysis’, 10(3), pp. 183–193. doi: 10.1053/j.arrt.2003.08.007.
Fudu, O. N. I., Eldman, J. O. F. and Riedman, E. L. I. A. F. (1996) ‘THE INTENSITY OF HEMODIALYSIS AND THE RESPONSE TO ERYTHROPOIETIN IN PATIENTS WITH END-STAGE RENAL DISEASE’, pp. 420–425.
Gafter, U. and Gafter-gvili, A. (2016) ‘Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis’, American Journal of Kidney Diseases. Elsevier Inc, 68(5), pp. 677–690. doi: 10.1053/j.ajkd.2016.04.018.
Ganz, T. and Nemeth, E. (2011) ‘Hepcidin and Disorders of Iron Metabolism’. doi: 10.1146/annurev-med-050109-142444.
Gaweda, A. E. et al. (2010) ‘Iron, Inflammation, Dialysis Adequacy, Nutritional Status, and Hyperparathyroidism Modify Erythropoietic Response’, Clin J Am Soc Nephrol, (5), pp. 576–581. doi: 10.2215/CJN.04710709.
Gluba-brz, A. et al. (2020) ‘The Influence of Inflammation on Anemia in CKD Patients’.
González-ortiz, A. et al. (2019) ‘Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin’. BMC Nephrology, pp. 1–9.
Gunnell, J. et al. (1999) ‘Acute-Phase Response Predicts Erythropoietin Resistance in Hemodialysis and Peritoneal Dialysis Patients’, 33(1), pp. 63–72.
Health ministry of Republic Indonesia (2018) ‘Air Bagi Kesehatan : Upaya Peningkatan Promotif Preventif Bagi Kesehatan Ginjal Di Indonesia’, Hasil Riset Kesehatan Dasar Kementrian Kesehatan RI, (Hari Ginjal Sedunia), p. 34. Available at: https://www.persi.or.id/images/2018/data/materi_menkes.pdf.
Indonesia, P. N. (2011) Konsensus Manajemen Anemia Pada Penyakit Ginjal Kronik. doi: 10.1017/CBO9781107415324.004.
Junior, W. V. de O. et al. (2015) ‘Inflammation and poor response to treatment with erythropoietin in chronic kidney disease’, J Bras Nefrol, 37(2), pp. 255–263. doi: 10.5935/0101-2800.20150039.
K.Singh, A. (2018) ‘Erythropoiesis: The Roles of Erythropoietin and Iron’, in Textbook of Nephro- Endocrinology, pp. 207–215. doi: 10.1016/B978-0-12-803247-3.00012-X.
Kalantar-zadeh, K. et al. (2010) ‘Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences’, American Journal of Kidney Diseases. National Kidney Foundation, Inc., 42(5), pp. 864–881. doi: 10.1016/j.ajkd.2003.07.016.
Keven, K. et al. (2003) ‘Randomized, Crossover Study of the Effect ofVitamin C on EPO Response in Hemodialysis Patients’, American Journal of Kidney Diseases, 41(6), pp. 1233–1239. doi: 10.1016/S0272-6386(03)00356-1.
Khan, A. M. (2017) ‘Hyperparathyroidism as a Predictor of Erythropoietin Resistance in Chronic Kidney Disease’, 5(2), pp. 1–7. doi: 10.15640/ijmp.v5n2a1.
Khankin, E. V et al. (2010) ‘Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease’, 5(2). doi: 10.1371/journal.pone.0009246.
Khedr, S. E. et al. (2017) ‘Erythropoietin hyporesponsiveness among egyptian hemodialysis patients’, Medicine Science International Medical Journal, 6(2), pp. 285–298. doi: 10.5455/medscience.2016.05.8559.
Kim, A. and Nemeth, E. (2016) ‘New insights into iron regulation and erythropoiesis’, Curr Opin Hematol, 22(3), pp. 199–205. doi: 10.1097/MOH.0000000000000132.New.
Kobayashi, H. et al. (2015) ‘Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis’, pp. 3783–3795. doi: 10.3390/nu7053783.
Komatsuda, A. et al. (1998) ‘Human parathyroid hormone does not influence human erythropoiesis in vitro’, Nephrol Dial Transplant, pp. 2088–2091.
Lacreta, G. et al. (2019) ‘Pure red cell aplasia and anti-erythropoietin antibodies in patients on hemodialysis: a report of two cases and a literature review’, Braz. J. Neprol, 41(1), pp. 145–151. doi: 10.1590/2175-8239-JBN-2018-0054.
Lewis, J. B. et al. (no date) ‘Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis’, pp. 493–503. doi: 10.1681/ASN.2014020212.
Liang, K. V, Zhang, J. H. and Palevsky, P. M. (2019) ‘Urea reduction ratio may be a simpler approach for measurement of adequacy of intermittent hemodialysis in acute kidney injury’. BMC Nephrology, pp. 1–7.
Lim, L. C. (2005) ‘Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure’, Hematology, 10(3), pp. 255–259. doi: 10.1080/10245330400026154.
Locatelli, F. and Vecchio, L. Del (2003) ‘Dialysis adequacy and response to erythropoietic agents : what is the evidence base ?’, pp. 29–35. doi: 10.1093/ndt/gfg1089.
Luo, J. et al. (2016) ‘Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients’, American Journal of Kidney Diseases. Elsevier Inc, 68(5), pp. 763–771. doi: 10.1053/j.ajkd.2016.05.031.
Ma, X. et al. (2015) ‘Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells’, F1000Research, 4(0), pp. 1–13. doi: 10.12688/f1000research.7010.1.
Macdougall, I. C. and Cooper, A. (2002) ‘The inflammatory response and epoetin sensitivity’, Nephrol Dial Transplant, 17, pp. 48–52.
Made, N. et al. (2015) ‘EFFECT OF DIALYZER REUSE UPON UREA REDUCTION RATIO ( URR ), KT / V UREA AND SERUM ALBUMIN IN REGULAR’, 26(3), pp. 166–170. doi: 10.14499/indonesianjpharm26iss3pp1.
Mcmurray, J. J. V et al. (2019) ‘Intravenous Iron in Patients Undergoing Maintenance Hemodialysis’, New England Journal of Medicine, pp. 447–458. doi: 10.1056/NEJMoa1810742.
Movilli, E. et al. (2001) ‘Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients’, (16), pp. 111–114.
Nand, N. et al. (2016) ‘Inflammation and erythropoietin hyporesponsiveness : Role of pentoxifylline , an anti TNF- a agent’, Journal Indian Academy of Clinical Medicine, 17(1), pp. 16–20.
Nathoo, B. et al. (2004) ‘A Cross-Sectional Immunosurveillance Study of Anti-EPO Antibody Levels in CRF Patients Receiving Epoetin Alfa in 5 Ontario Renal Centers’, 44(2), pp. 264–269. doi: 10.1053/j.ajkd.2004.04.031.
Nemeth, E. and Ganz, T. (2014) ‘Anemia of Inflammation’, Hematology/Oncology Clinics of NA. Elsevier Inc, 28(4), pp. 671–681. doi: 10.1016/j.hoc.2014.04.005.
Neto, L. C. et al. (2016) ‘The Role of Zinc in Chronic Kidney Disease Patients on Hemodialysis : A Systematic Review’, (February), pp. 344–352.
Nitta, K. et al. (2002) ‘Inflammation and Resistance to Erythropoietin in Hemodialysis Patients’, Acta Haematol, 108, pp. 168–170.
Nowrousian, M. R. (2002) ‘Pathophysiology of cancer-related anemia’, in Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology, pp. 39–62.
Olcay, I. et al. (2007) ‘Effect of protein-energy malnutrition on erythropoietin requirement in maintenance hemodialysis patients’, pp. 198–203.
Oshvandi, K. et al. (2014) ‘High-Flux and Low-Flux Membranes : Efficacy in Hemodialysis’, 3(3).
Panagoutsos, S. A. et al. (2001) ‘The Clinical Impact of Increasing the Hemodialysis Dose’, Hemodialysis International, 5, pp. 51–54.
Panagoutsos, S. A. et al. (2009) ‘EFFECTS OF HEMODIALYSIS DOSE ON ANEMIA , HYPERTENSION , AND NUTRITION’, 6049. doi: 10.1081/JDI-120013965.
Papanikolaou, G. and Pantopoulos, K. (2017) ‘Systemic iron homeostasis and erythropoiesis’, IUBMB Life, 69(6), pp. 399–413. doi: 10.1002/iub.1629.
Paper, O. (2007) ‘Prevalence of Anti-Erythropoietin Antibodies in Hemodialysis Patients without Clinical Signs of Pure Red Cell Aplasia’, pp. 90–99. doi: 10.1159/000097889.
Paulson, R. F. et al. (2020) ‘Stress Erythropoiesis is a Key Inflammatory Response’, pp. 1–14.
Rao, D. S., Shih, M.-S. and Mohini, R. (1993) ‘Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on The Response to Erythropoietin in Uremia’, The New England journal of medicine, (328), pp. 171–5.
Rattanasompattikul, M. et al. (2013) ‘Association of malnutrition – in fl ammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients’, 6(October 2012), pp. 1936–1945. doi: 10.1093/ndt/gfs368.
Reddy, G. C., Devaki, R. and Rao, P. (2013) ‘Iron Indices In Patients With Functional AnemiaL In Chronic Kidney Disease’, The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 24(iv), pp. 1–8.
Richardson, D. et al. (2003) ‘A Randomized, Controlled Study of the Consequences of Hemodialysis Membrane Composition on Erythropoietic Response’, 42(3), pp. 551–560. doi: 10.1016/S0272-6386(03)00788-1.
Rodby, R. A. et al. (2015) ‘Ferric Citrate , an Iron-Based Phosphate Binder , Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data’, Drugs in R&D. Springer International Publishing, 15(3), pp. 271–279. doi: 10.1007/s40268-015- 0103-y.
Saran, K. Al, Sabry, A. and Hassan, A. H. (2013) ‘Effect of Relative Hypoparathyroidism on the Responsiveness to Recombinant Human Erythropoietin in Chronic Hemodialysis Patients : A Single Saudi Center Experience’, Saudi J Kidney Dis Transpl, 24(4), pp. 825–831.
Schneider, A. et al. (2013) ‘Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes’, BMC Nephrology. BMC Nephrology, 14(1), p. 1. doi: 10.1186/1471- 2369-14-67.
Seifollah, S. et al. (2016) ‘Association of secondary hyperparathyroidism with anemia in patients with end-stage renal disease ; a review on current knowledge’, 4(2), pp. 48–53.
Smrzova, J., Balla, J. and Ba, P. (2005) ‘Inflammation and resistance to erythropoiesis- stimulating agents — what do we know and what needs to be clarified ?’, pp. 2–7. doi: 10.1093/ndt/gfh1109.
Sultana, T., Devita, M. V and Michelis, M. F. (2016) ‘Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency’, International Urology and Nephrology. Springer Netherlands, 48(9), pp. 1519–1524. doi: 10.1007/s11255-016-1309-9.
Tarng, D.-C. et al. (1999) ‘Erythropoietin hyporesponsiveness From iron deficiency to iron overload.pdf’, Kidney International, 55(69), pp. 107–118.
Tarng, D.-C., Chen, T. W. and Huang, T.-P. (1995) ‘Iron Metabolism Indices for Early Prediction of the Response and Resistance to Erythropoietin Therapy in Maintenance Hemodialysis Patients’, Am J Nephrol, 15, pp. 230–237.
Umanath, K. et al. (2015) ‘Ferric Citrate Reduces Intravenous Iron and Erythropoiesis- Stimulating Agent Use in ESRD’, pp. 1–10. doi: 10.1681/ASN.2014080842.
Xing, X., Zhang, W. and Sun, H. (2016) ‘Role of Erythropoietin in Renal Anemia Therapy’, Tropical Journal of Pharmaceutical Research, 15(5), pp. 1083–1088.
Yegenaga, I. and Aydin, Z. (2014) ‘Low Serum Zinc Level May be Related to Higher Doses of EPO in Hemodialysis Patients’, BANTAO Journal, 12(1), pp. 40–44. doi: 10.2478/bj- 2014-0009.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Universitas Ahmad Dahlan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License and Copyright Agreement
In submitting the manuscript to the journal, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal. Please also carefully read Ahmad Dahlan Medical Journal posting Your Article Policy.
- That it is not under consideration for publication elsewhere.
- That its publication has been approved by all the author(s) and by the responsible authorities - tacitly or explicitly - of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
Copyright
Authors who publish with Ahmad Dahlan Medical Journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
